Capture of endothelial progenitor cells by a bispecific protein/monoclonal antibody molecule induces reendothelialization of vascular lesions
- 241 Downloads
Tissue injury is inevitably accompanied by disruption of the endothelium and exposure of the subendothelial matrix. To generate a guidance molecule directing progenitor cells to sites of vascular lesions, we designed a bifunctional protein. The protein consists of the soluble platelet collagen receptor glycoprotein VI and an antibody to CD133 (hereafter called GPVI-CD133). In vitro and in vivo, this construct substantially mediates endothelial progenitor cell (EPC) homing to vascular lesions. Exposure of EPCs to GPVI-CD133 did not impair their capability to differentiate toward mature endothelial cells as verified by the formation of colony-forming units, the upregulation of endothelial markers CD31 and CD146 analyzed by flow cytometry or von Willebrand factor and endoglin assessed by immunofluorescence microscopy, as well as the presence of Weibel–Palade bodies using transmission electron microscopy. In vivo, GPVI-CD133 augments reendothelialization of vascular lesions. Thus, this bifunctional protein could be a potential new therapeutic option for cardiovascular diseases.
KeywordsRegenerative medicine Endothelialization Progenitor cells Stem cells Vascular injury Guidance molecule Vascular disease Therapy
We acknowledge the excellent technical assistance of Sarah Gehring, Jadwiga Kwiatkowska, Heike Runge, Sandra Bundschuh, and Birgit Fehrenbacher. We thank Rupert Handgretinger for critical revision and supply of stem cells.
The study was supported by grants from the Deutsche Forschungsgemeinschaft (Graduiertenkolleg “Zellbiologische Mechanismen immunasoziierter Prozesse,” GK 794 and “Vaskuläre Medizin” [GRK 438 and MA 2186/3-1] to MG), SFB-TR19, and the Novartis Foundation and the fortüne research program of the UKT to HFL and MG. The Bio-Rad TPLSM was obtained via a grant (no. 902-16-276) from the Medical Section of the Dutch Scientific Organization. Experiments carried out by JW v.d. R, SC, and TS were financed by the Center for Regeneration Biology and Regenerative Medicine by the Carl Baresel Stiftung and Stiftung Landesbank Baden Württemberg.
Potential conflict of interest
Dynamic adhesion of EPCs to GPVI-CD133 in vitro (a). Under arterial shear conditions (2,000 s−1), adhesion of EPCs to collagen additionally covered with the individual components of the construct (10 μg/mL each) is shown from minute 08:30 to minute 09:00 of perfusion. Virtually no firm adhesion of EPCs could be observed (MOV 264 kb)
Dynamic adhesion of EPCs to GPVI-CD133 in vitro (b). This sequence from minute 06:00 to minute 09:00 is representative for flow chamber experiments, in which the bispecific construct (10 μg/mL) was applied. Adherent EPCs are distributed over the complete frame (MOV 3252 kb)
Recruitment of EPCs to vascular lesions by GPVI-CD133 in vivo (a). In C57BL/6J mice, the common carotid artery was injured by ligation and DCF (green)-stained EPCs were injected intravenously. When the cells were incubated with both individual components of the construct, significantly less EPCs adhered to the injured vessel wall than in (MOV 1429 kb)
Recruitment of EPCs to vascular lesions by GPVI-CD133 in vivo (b) experiments with EPCs treated with the GPVI-CD133 construct. Both films are recorded 30 min after the induction of vascular injury (MOV 2292 kb)
Z-stack movie (see also supplemental figure 1) as imaged by TPLSM of an intact, nonvital carotid artery mounted in a flow chamber (obtained from intravital microscopy experiments) (a) (MOV 3660 kb)
EPCs were incubated with the GPVI-CD133 construct, but the carotid artery is intact. Screening starts from the luminal side of the vessel. First, the endothelial monolayer (red nuclei), then the media and the adventitia become visible. The media shows smooth muscle cell nuclei (red), the adventitia fibroblasts (red nuclei) embedded in collagen (blue, SHG). No DCF stained EPCs can be observed on the luminal side of the vessel (b) (MOV 1667 kb)
- 4.Conrad S, Renninger M, Hennenlotter J, Wiesner T, Just L, Bonin M, Aicher W, Buhring HJ, Mattheus U, Mack A, Wagner HJ, Minger S, Matzkies M, Reppel M, Hescheler J, Sievert KD, Stenzl A, Skutella T (2008) Generation of pluripotent stem cells from adult human testis. Nature 456:344–349CrossRefPubMedGoogle Scholar
- 6.Moretti A, Caron L, Nakano A, Lam JT, Bernshausen A, Chen Y, Qyang Y, Bu L, Sasaki M, Martin-Puig S, Sun Y, Evans SM, Laugwitz KL, Chien KR (2006) Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell 127:1151–1165CrossRefPubMedGoogle Scholar
- 11.Massberg S, Konrad I, Bultmann A, Schulz C, Munch G, Peluso M, Lorenz M, Schneider S, Besta F, Muller I, Hu B, Langer H, Kremmer E, Rudelius M, Heinzmann U, Ungerer M, Gawaz M (2004) Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 18:397–399PubMedGoogle Scholar
- 15.Bühring H, Marxer A, Lammers R, Wissinger B (2002) CD133 cluster report. In: Mason D, André P, Bensussan A, Buckley C, Civin C, Clark E, de Haas M, Goyert S, Hadam M, Hart D, Hoøejší V, Jones Y, Meuer S, Morrissey J, Schwartz-Albiez R, Shaw S, Simmons D, Turni L, Uguccioni M, van der Schoot E, Vivier E, Zola H (eds) Leucocyte Typing VII. White Cell Differentiation Antigens. Oxford University Press, Oxford, pp 622–623Google Scholar
- 18.Choi EY, Chavakis E, Czabanka MA, Langer HF, Fraemohs L, Economopoulou M, Kundu RK, Orlandi A, Zheng YY, Prieto DA, Ballantyne CM, Constant SL, Aird WC, Papayannopoulou T, Gahmberg CG, Udey MC, Vajkoczy P, Quertermous T, Dimmeler S, Weber C, Chavakis T (2008) Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. Science 322:1101–1104CrossRefPubMedGoogle Scholar
- 20.Langer H, May AE, Daub K, Heinzmann U, Lang P, Schumm M, Vestweber D, Massberg S, Schonberger T, Pfisterer I, Hatzopoulos AK, Gawaz M (2006) Adherent platelets recruit and induce differentiation of murine embryonic endothelial progenitor cells to mature endothelial cells in vitro. Circ Res 98:e2–e10CrossRefPubMedGoogle Scholar
- 27.Massberg S, Konrad I, Schurzinger K, Lorenz M, Schneider S, Zohlnhoefer D, Hoppe K, Schiemann M, Kennerknecht E, Sauer S, Schulz C, Kerstan S, Rudelius M, Seidl S, Sorge F, Langer H, Peluso M, Goyal P, Vestweber D, Emambokus NR, Busch DH, Frampton J, Gawaz M (2006) Platelets secrete stromal cell-derived factor 1α and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med 203:1221–1233CrossRefPubMedGoogle Scholar
- 29.Muller I, Kordowich S, Holzwarth C, Spano C, Isensee G, Staiber A, Viebahn S, Gieseke F, Langer H, Gawaz M, Horwitz E, Conte P, Handgretinger R, Dominici M (2006) Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 8:437–444CrossRefPubMedGoogle Scholar
- 30.Langer HF, Stellos K, Steingen C, Froihofer A, Schonberger T, Kramer B, Bigalke B, May AE, Seizer P, Muller I, Gieseke F, Siegel-Axel D, Meuth SG, Schmidt A, Wendel HP, Muller I, Bloch W, Gawaz M (2009) Platelet derived bFGF mediates vascular integrative mechanisms of mesenchymal stem cells in vitro. J Mol Cell Cardiol 47:315–325CrossRefPubMedGoogle Scholar
- 38.Sasaki K, Heeschen C, Aicher A, Ziebart T, Honold J, Urbich C, Rossig L, Koehl U, Koyanagi M, Mohamed A, Brandes RP, Martin H, Zeiher AM, Dimmeler S (2006) Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci U S A 103:14537–14541CrossRefPubMedGoogle Scholar